New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 15, 2012
05:13 EDTSBUX, NLY, GLD, DNDN, HD, EXC, SIRI, BAC, ZIP, ZNGA, CL, PM, PCAR, CMI, AMRC, AGNC, LOW, DECK, WFMI, JPM, MDVN, IDIX, CONN, MNST, SXCI, PCLN, MSFT, IBM, VVUS, ACAT, HSTM, REGN, QCOR, GS, YHOO, AAPL, KO, PCYC, PFEJim Cramer's "Mad Money"
Wednesday was Jim Cramer's anniversary of his "Mad Money" TV show. He said it's time to come off the sidelines, sell those bank CDs earning 0.4% interest and invest in great American companies. Cramer said today's markets are being driven by pure growth, U.S. growth. He said everything from health care to retail to technology, even the homebuilders, are just beginning to show sustainable recoveries. Stocks like JPMorgan Chase (JPM) and IBM (IBM), are both leading the charge. Then there's Apple (AAPL) Cramer said while some investors can't fathom Apple's historic rise, he remembers a time when Coca-Cola (KO) and Pfizer (PFE) were the most valued companies on Wall Street. Apple is so much more than just a technology company, he said, adding it's a communications, education and entertainment company as well, all of which makes it worth its valuation. Cramers said the markets can most certainly take out its recent highs and march into bull-market mode, with a pickup in commercial construction and improved job growth looming just around the corner. Cramer recapped his "Magnificent Seven" speculative stocks to show viewers just how lucrative this under-rated method of investing can be. He said that every investor should have one spot in their portfolio dedicated to a speculative stock that adds excitement to their holdings. Cramer's magnificent seven stocks included Pharmacyclics (PCYC), a stock up 393% over the past 12 months, Medivation (MDVN), a biotech up 320%, Idenix Pharmaceuticals (IDIX), up 277%, and Vivus (VVUS), up 224%. Rounding out the seven were Arctic Cat (ACAT), which has risen 204% in 12 months, Conn's (CONN), up 211% and HealthStream (HSTM), which is up 192%. Next, Cramer also highlighted the seven best stocks that he's recommended since "Mad Money" first aired back in 2005, a list that exemplifies what "staying in the game" is all about. His top seven recommendations included Monster Beverage (MNST), which has risen 1,600% over the past seven years, the biotech company Regeneron (REGN), up 1,700% over seven years and Medivation (MDVN), the only company to make both of Cramer's lists, up 1,800%. The list also included Green Mountain Coffee Roasters (GMCR), a stock that despite huge losses recently, is still up 2,700% over seven years, SXC Health Solutions (SXCI) up 2800%, travel site Priceline.com (PCLN), up 2,850% and finally, Questcor Pharmceuticals (QCOR), which has rallied an astounding 7,066% over seven years. Cramer said when companies are riding long-term trends, their successes can turn into huge gains for shareholders. Next, Cramer responded to a New York Times op-ed piece chastising Goldman Sachs (GS), saying that the company often put its own interests ahead of those of its clients. Cramer said he didn't see any of this type of behavior when he worked for Goldman years ago. He said while he's sure that many of Goldman's employees are still committed to doing right by clients, perhaps this article can serve as a wake-up call for the firm to do even better for its clients, even if that means being less profitable in the short term. MAD TWEETS: Cramer said that Microsoft (MSFT) was a good stock, Yahoo (YHOO) was a bad one and Sirius XM Radio (SIRI) was a speculative one. Deckers Outdoor (DECK), said the warm winter hit this cold-weather shoemaker hard. Cramer was bullish on Starbucks (SBUX). Restructuring is working at Lowes (LOW) but he still prefers Home Depot (HD), and with gold stocks still suffering, he still likes the SPDR Gold Shares (GLD). Finally when asked about ZipCar (ZIP), Cramer said if investors want to invest in a recent IPO, he'd go with mobile game maker Zynga (ZNGA). LIGHTNING ROUND: (Bullish) ECL;PM; PCAR; CMI; AGNC; NLY; AMRC; EXC; WFMI. (Bearish) DNDN; BAC. Reference Link
News For DECK;SIRI;NLY;AGNC;YHOO;MSFT;CMI;GS;PCLN;PCAR;QCOR;SXCI;PM;REGN;MNST;CL;HSTM;CONN;ZNGA;ACAT;IDIX;ZIP;VVUS;MDVN;BAC;HD;JPM;PCYC;DNDN;PFE;KO;GLD;WFMI;AAPL;IBM;LOW;EXC;SBUX;AMRC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | all recent news | >>
January 12, 2015
09:42 EDTNLY, AGNCWells cuts Mortgage REIT space to Market Weight from Overweight
Subscribe for More Information
09:35 EDTEXCExelon upgraded to Buy from Hold at Tudor Pickering
Subscribe for More Information
09:34 EDTNLYAnnaly Capital downgraded to Market Perform from Outperform at Wells Fargo
Subscribe for More Information
09:34 EDTAAPLActive equity options trading
Subscribe for More Information
09:31 EDTAGNCAmerican Capital downgraded to Market Perform from Outperform at Wells Fargo
Subscribe for More Information
09:22 EDTPFE23andMe announces collaboration with Pfizer
Google (GOOG)-backed 23andMe announced an agreement with Pfizer (PFE) that will provide Pfizer with access to 23andMe’s research platform, including services and Research Portal analysis of 23andMe’s genotyped population of over 800,000 individuals, of which more than 80 percent have consented to participate in research. 23andMe’s Research Portal enables qualified and approved scientists outside of 23andMe the opportunity to leverage the company’s unique research model while still protecting the privacy and security of 23andMe’s customers. As a part of the agreement, the companies will collaborate on certain genome-wide association studies, surveys, and clinical trial recruitment. One of these collaborations will be a longitudinal study to better understand the genetics of lupus. This study will entail enrollment and genotyping of 5,000 people into a new lupus research community, and include the integration of medical records, targeted bio-sampling along with genetic information for all participants. This announcement follows a collaboration between 23andMe and Pfizer to enroll 10,000 people with Inflammatory Bowel Disease in a research initiative designed to explore the genetic factors associated with the onset, progression, severity and response to treatments for IBD. Nearly 4,000 patients have been enrolled in the community since August 2014.
08:43 EDTPCARPACCAR upgraded at RBC Capital
As noted earlier, RBC Capital upgraded PACCAR to Outperform from Sector Perform. The firm believes the company is poised to benefit from an improving North American truck cycle, and says that the company's customers should benefit from lower fuel prices. Target to $75 from $66.
08:37 EDTPFEShire deal suggests most biotech companies in play, says JMP Securities
After Shire (SHPG) agreed to buy NPS Pharmaceuticals (NPSP), JMP Securities says the deal indicates that most biotech companies are in play, particularly those with worldwide rights to their products for well-defined patient populations. The firm expects investors to speculate all week about potential new targets in the space. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
08:22 EDTJPMCiti may have more to gain than JPMorgan from break-up, WSJ says
Analysts have suggested that JPMorgan (JPM) could unlock investor value by breaking-up, but a Citigroup (C) break-up, while complicated, could be more compelling, according to The Wall Street Journal's "Heard on the Street" column. Reference Link
08:21 EDTAAPLApple poised to gain market share, says JMP Securities
Subscribe for More Information
08:11 EDTEXCExelon comments on Illinois nuclear power plant report
Exelon issued the following statement on the State of Illinois report on potential nuclear power plant closings prepared in response to House Resolution 1146: "We thank the state for its attention and work on such an important issue for Illinois and the future of the state’s energy assets. The report confirms that the state’s six nuclear power plants provide substantial economic and environmental benefits to Illinois residents and businesses. It also highlights the negative impacts closing one or more of the state’s nuclear facilities prematurely would have on Illinois’ economy, energy prices and carbon emissions, and concerns it would raise about the reliability of the electric grid. The report makes clear that the future of Illinois’ nuclear power plants should be an issue of statewide concern... The report finds that closing the three Illinois nuclear plants at greatest risk of early retirement would have a significant negative economic impact on the state, including $1.8 billion in annual lost economic activity and more than 7,800 job losses, and that the resulting increase in carbon emissions would have a societal cost of more than $18 billion. It also concludes that the closures would increase wholesale electricity costs in the northern Illinois region served by ComEd by up to 9.9 percent, or $437 million, in the first year... We continue to believe that the best, most cost-effective approach for preserving the benefits these plants provide is a market-based solution that properly values the emissions-free, always-on energy they generate. The report presents several potential policy solutions and is a good starting point for discussions with lawmakers and other stakeholders about the right path forward for continuing to meet Illinois’ energy needs."
08:05 EDTMSFTGameStop to use Microsoft Azure to stream game content, promotional materials
Subscribe for More Information
07:52 EDTIBMIBM to undertake biggest re-organization in company history, Register says
Subscribe for More Information
07:52 EDTIBMIBM price target lowered to $130 from $144 at Jefferies
Jefferies lowered its price target for IBM shares to $130 after cutting its estimates to reflect the strengthening of the dollar against almost every other major currency worldwide since the tech giant reported Q3 results. Jefferies believes consensus estimates for IBM need to come down as the company deals with enterprises increasingly allocating investments away from traditional Software and IT Outsourcing toward investments in Cloud, Mobile and and Social initiatives. The firm reiterates an Underperform rating on IBM.
07:41 EDTJPMLarge banks' weakness creates attractive entry point, says Wells Fargo
Subscribe for More Information
07:35 EDTIBMNational Retail Federation to hold a trade show
Subscribe for More Information
06:46 EDTPCARPACCAR upgraded to Outperform from Sector Perform at RBC Capital
Subscribe for More Information
06:14 EDTGSBrennan Investment, Goldman Sachs acquire industrial portfolio
Subscribe for More Information
06:12 EDTYHOOStocks with implied volatility above IV index mean; HLF YHOO
Stocks with implied volatility above IV index mean; Herbalife (HLF) 114, Yahoo (YHOO) 50 according to iVolatility.
06:03 EDTGLDSPDR Gold Trust overall implied volatility at 17; 26-week average is 17
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use